Menopausal Hormone Therapy In Breast Cancer Survivors: A Meta-analysis Study Of The Risk Of Recurrence

Objective: System evaluate the recurrence rate, the local recurrence and distantmetastasis rate, mortality rate related to breast cancer and overall mortality ofwhom accept postmenopausal hormone therapy (menopausal hormone therapy,MHT) after surgery in patients with breast cancer.Material and Method:According to the requirements of the Cochrane collaborationliterature retrieval, databases including PubMed, Medline, Embase, CochraneLibrary, SciFinder, CNKI, China journal full text database(CJFD),Googlescholar,WanFang,Weipu Chinese periodical full text database were searched forrelevant literatures in Chinese and English which were published during1990.01~2014.01by computer,at the same time,supplemented by hand searchingthe scope for the Jinlin University library.In strict accordance with inclusioncriteria and exclusion criteria formulation screening study,software RevMan5.3was used for Meta analysis of the relevant datas extracted from the homogeneitystudies included.Results: Eventually included four studies were cohort studies, including one forthe bi-cohort study, a prospective cohort study of more than both, a total of1173subjects who were breast cancer patients, with an average age of50to60yearsold among which there were418women to accept postmenopausal hormonetherapy (menopausal hormone therapy, MHT). In this study, the rate of recurrence, local recurrence rate, distant metastasis rate, mortality related tobreast cancer and overall mortality were compared for Meta analysis betweenpatients with breast cancer accepting MHT and none MHT. The results show that:patients with MHT group than no MHT group:①There was no significantdifference in recurrence rate (RR=1.05,95%CI of (0.76,1.46), and P>0.05);②local recurrence rate was no significant difference (RR=0.68,95%CI of(0.36,1.28), and P>0.05);③distant metastasis rate was no significant difference(RR=1.31,95%CI of (0.82,2.08), and P>0.05);④breast cancer-relatedmortality difference was not statistically significant (RR=0.85,95%CI of(0.41,1.77), and P>0.05);⑤Also,there was no significant difference in overallmortality (RR=1.00,95%CI of (0.74,1.36), and P>0.05). that is to say, MHT inbreast cancer survivors did not increase total mortality，recurrence rate，localrecurrence rate，distant metastasis rate as well as breast cancer-related mortality.Conclusion: There was no statistically significance between MHT group and noMHT group after obtaining breast cancer surgery in rate of relapse, localrecurrence, distant metastasis, breast cancer-related mortality as well as totalmortality. So the present study can not confirm that accepting MHT in breastcanser survivors will increase all above mentioned poor outcomes.